• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-time longitudinal analysis of human gliomas reveals in vivo genome evolution and therapeutic impact under standardized treatment.

作者信息

Xu Sensen, Sheng Zhiyuan, Yu Jinliang, Deng Kaiyuan, Wu Shuang, Bu Yage, Guo Guangzhong, Zhang Ziyue, Liu Guanzheng, Gao Yushuai, Yan Zhaoyue, Bu Chaojie, He Yingkun, Liu Gang, Zemmar Ajmal, Hernesniemi Juha, Kong Lingfei, Wang Meiyun, Li Tianxiao, Bu Xingyao

机构信息

Department of Neurosurgery, Juha International Center for Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, China.

Department of Psychological Medicine, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, China.

出版信息

Clin Transl Med. 2022 Jul;12(7):e956. doi: 10.1002/ctm2.956.

DOI:10.1002/ctm2.956
PMID:35802830
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9269997/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef8/9269997/912c20a47e1a/CTM2-12-e956-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef8/9269997/d03e03317533/CTM2-12-e956-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef8/9269997/57292805e92b/CTM2-12-e956-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef8/9269997/3857939ae5f5/CTM2-12-e956-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef8/9269997/912c20a47e1a/CTM2-12-e956-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef8/9269997/d03e03317533/CTM2-12-e956-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef8/9269997/57292805e92b/CTM2-12-e956-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef8/9269997/3857939ae5f5/CTM2-12-e956-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef8/9269997/912c20a47e1a/CTM2-12-e956-g004.jpg

相似文献

1
Real-time longitudinal analysis of human gliomas reveals in vivo genome evolution and therapeutic impact under standardized treatment.对人类胶质瘤的实时纵向分析揭示了标准化治疗下的体内基因组进化及治疗影响。
Clin Transl Med. 2022 Jul;12(7):e956. doi: 10.1002/ctm2.956.
2
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium.通过 GLASS 观察神经胶质瘤：弥漫性神经胶质瘤的分子进化和神经胶质瘤纵向分析联盟。
Neuro Oncol. 2018 Jun 18;20(7):873-884. doi: 10.1093/neuonc/noy020.
3
[Molecular Classification and Personalized Treatment of Gliomas].[胶质瘤的分子分类与个体化治疗]
No Shinkei Geka. 2016 Mar;44(3):185-201. doi: 10.11477/mf.1436203256.
4
Update in the treatment of high-grade Gliomas.高级别胶质瘤治疗的新进展。
Neurol Clin. 2013 Aug;31(3):847-67. doi: 10.1016/j.ncl.2013.03.005. Epub 2013 Apr 6.
5
[Oncolytic viral therapy of gliomas: review of the literature].[胶质瘤的溶瘤病毒疗法：文献综述]
Neurocirugia (Astur). 2005 Apr;16(2):158-68. doi: 10.1016/s1130-1473(05)70421-8.
6
Neuro-oncology: new hope for patients with gliomas.神经肿瘤学：胶质瘤患者的新希望。
Lancet Neurol. 2010 Jan;9(1):17-8. doi: 10.1016/S1474-4422(09)70326-6.
7
[Molecular genetic analysis for malignant gliomas: clinical implications and future directions].[恶性胶质瘤的分子遗传学分析：临床意义与未来方向]
No Shinkei Geka. 2008 Jan;36(1):83-91.
8
An integrated approach to identifying clinically relevant targets in pediatric gliomas.一种识别小儿胶质瘤临床相关靶点的综合方法。
CNS Oncol. 2013 Jul;2(4):303-6. doi: 10.2217/cns.13.21.
9
Longitudinal genomic characterization of brain tumors for identification of therapeutic vulnerabilities.脑肿瘤的纵向基因组特征分析以确定治疗易感性。
Neuro Oncol. 2016 Aug;18(8):1037-9. doi: 10.1093/neuonc/now064. Epub 2016 May 28.
10
Radio-responsive TRAIL gene therapy for malignant gliomas.用于恶性胶质瘤的放射反应性TRAIL基因治疗
Cancer Gene Ther. 2007 Dec;14(12):1002. doi: 10.1038/sj.cgt.7701083. Epub 2007 Aug 17.

引用本文的文献

1
Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas.动态原位肿瘤液体循环肿瘤DNA术后有效预测胶质母细胞瘤的复发及临床获益
Neurosurgery. 2025 Mar 5;97(3):671-80. doi: 10.1227/neu.0000000000003384.
2
Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study.动态监测循环肿瘤DNA以预测术后胶质瘤非原位复发风险：一项前瞻性队列研究
Cancer Med. 2025 Mar;14(5):e70733. doi: 10.1002/cam4.70733.
3
Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.

本文引用的文献

1
Integrating real-time in vivo tumour genomes for longitudinal analysis and management of glioma recurrence.整合实时体内肿瘤基因组用于胶质瘤复发的纵向分析和管理。
Clin Transl Med. 2021 Nov;11(11):e567. doi: 10.1002/ctm2.567.
2
Tumor DNA From Tumor Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence.来自肿瘤液的肿瘤DNA揭示了胶质瘤手术后微小残留病的突变图谱及早期复发风险。
Front Oncol. 2021 Oct 11;11:742037. doi: 10.3389/fonc.2021.742037. eCollection 2021.
3
Identification of Hub Genes and Key Pathways Associated with Anti- Resistant Glioblastoma Using Gene Expression Data Analysis.
复发性胶质母细胞瘤中肿瘤原位液循环肿瘤 DNA 的动力学预测免疫检查点阻断联合低剂量贝伐珠单抗治疗的疗效。
J Cancer Res Clin Oncol. 2024 Oct 18;150(10):466. doi: 10.1007/s00432-024-05997-8.
4
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.利用原位肿瘤液循环肿瘤 DNA 分析预测免疫检查点抑制和低剂量贝伐珠单抗治疗复发性胶质母细胞瘤的临床结局。
Cancer Immunol Immunother. 2024 Aug 6;73(10):193. doi: 10.1007/s00262-024-03774-7.
5
Tracking tumor evolution during the first-line treatment in brain glioma serial profiling of cell-free tumor DNA from tumor fluid.追踪脑胶质瘤一线治疗期间的肿瘤演变：对肿瘤液体中游离肿瘤DNA进行连续分析。
Front Oncol. 2023 Oct 17;13:1238607. doi: 10.3389/fonc.2023.1238607. eCollection 2023.
基于基因表达数据分析鉴定与抗耐药性胶质母细胞瘤相关的枢纽基因和关键通路。
Biomolecules. 2021 Mar 9;11(3):403. doi: 10.3390/biom11030403.
4
Frontiers in the treatment of glioblastoma: Past, present and emerging.胶质母细胞瘤治疗的前沿：过去、现在和未来。
Adv Drug Deliv Rev. 2021 Apr;171:108-138. doi: 10.1016/j.addr.2021.01.012. Epub 2021 Jan 21.
5
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.EANO 成人弥漫性胶质瘤诊断与治疗指南。
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186. doi: 10.1038/s41571-020-00447-z. Epub 2020 Dec 8.
6
Longitudinal molecular trajectories of diffuse glioma in adults.成人弥漫性神经胶质瘤的纵向分子轨迹。
Nature. 2019 Dec;576(7785):112-120. doi: 10.1038/s41586-019-1775-1. Epub 2019 Nov 20.
7
Reconstructing the molecular life history of gliomas.重建神经胶质瘤的分子生命史。
Acta Neuropathol. 2018 May;135(5):649-670. doi: 10.1007/s00401-018-1842-y. Epub 2018 Apr 3.
8
Overcoming therapeutic resistance in glioblastoma: the way forward.克服胶质母细胞瘤的治疗耐药性：前进的道路。
J Clin Invest. 2017 Feb 1;127(2):415-426. doi: 10.1172/JCI89587.
9
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.分子分析揭示弥漫性胶质瘤的生物学离散亚群和进展途径。
Cell. 2016 Jan 28;164(3):550-63. doi: 10.1016/j.cell.2015.12.028.
10
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.贝伐珠单抗联合放疗-替莫唑胺治疗新诊断的胶质母细胞瘤。
N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.